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Abstract: Background: indeterminate Western blot (WB) patterns are a major concern for diagnosis
of human T-cell lymphotropic virus type 1 (HTLV-1) infection, even in non-endemic areas.
Objectives: (a) to define the prevalence of indeterminate WB among different populations from
Argentina; (b) to evaluate if low proviral load (PVL) is associated with indeterminate WB profiles;
and (c) to describe mutations in LTR and tax sequence of these cases. Results: Among 2031 samples,
294 were reactive by screening. Of them, 48 (16.3%) were WB indeterminate and of those 15 (31.3%)
were PCR+. Quantitative real-time PCR (qPCR) was performed to 52 HTLV-1+ samples, classified as
Group 1 (G1): 25 WB+ samples from individuals with pathologies; Group 2 (G2): 18 WB+ samples
from asymptomatic carriers (AC); and Group 3 (G3): 9 seroindeterminate samples from AC. Median
PVL was 4.78, 2.38, and 0.15 HTLV-1 copies/100 PBMCs, respectively; a significant difference
(p=0.003) was observed. Age and sex were associated with PVL in G1 and G2, respectively.
Mutations in the distal and central regions of Tax Responsive Elements (TRE) 1 and 2 of G3 were
observed, though not associated with PVL.The 8403A>G mutation of the distal region, previously
related to high PVL, was absent in G3 but present in 50% of WB+ samples (p = 0.03). Conclusions:
indeterminate WB results confirmed later as HTLV-1 positive may be associated with low PVL levels.
Mutations in LTR and tax are described; their functional relevance remains to be determined.
Keywords: HTLV-1/2; proviral load; Western blot; indeterminate; mutations
1. Introduction
Human T-cell lymphotropicvirus type 1 and 2 (HTLV-1/2) are distributed worldwide. HTLV-1
infects an estimated 20 million people in the world and is considered the etiologic agent of
adult T-cell leukemia/lymphoma (ATLL), HTLV-associated myelopathy/tropical spastic paraparesis
(HAM/TSP), and HTLV-1 uveitis [1]. HTLV-1 presents foci of endemicity in the Caribbean,
Southeastern Japan, sub-Saharan Africa, the Middle East, and areas of South America, while HTLV-2
is naturally endemic in natives from Africa and aborigines of the Americas [1,2]. Concerning
phylogeny, seven subtypes have been identified within HTLV-1: cosmopolitan (a), Central African
(b and d), Melanesian (c), a variant from Zaire (e), one from Gabon (f), and one from
Cameroon (g). The cosmopolitan subtype, disseminated worldwide, is composed of five subgroups:
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transcontinental (A), Japanese (B), West African (C), North African (D), and Black Peruvian (E) [3–5].
In Argentina, HTLV-1 cosmopolitan subtype transcontinental subgroup A is the major subgroup
detected in the endemic area of thenorthwest as well as in blood donors, pregnant women, and
different at-risk populations in non-endemic regions [6,7].
Mandatory screening for HTLV-1/2 in blood banks, which includes detection by an enzyme
immunoassay (EIA) or particle agglutination (PA), has been implemented in many countries so
far. According to the current algorithm, a serological confirmation, usually by Western blot (WB),
should be performed after reactive screening results [8]. However, despite improvements made in
the WB assay specificity over the past years, HTLV-indeterminate WB results continue to be frequent
in blood donors, mainly in inter-tropical areas, posing a major challenge for routine diagnosis
worldwide [9–11].
It has been observed that the use of screening tests with low specificity significantly increases the
number of indeterminate WB results that are later confirmed negative for the infection by molecular
techniques [12]. Other possible explanations include cross-reactivity against other retroviruses or
microbial agents, as occurs with Plasmodium falciparum in Central Africa, Indonesia, and the
Philippines [13–15]. Regarding seroindeterminate cases later confirmed positive for the infection,
several hypotheses have been proposed such as the presence of defective virus or low copy numbers
of prototypic HTLV-1/2 that could be yielding a light antibody response [16]. Punctual mutations in
key viral genes could be another alternative. Netto et al. have reported an association between G232A
in the Tax Responsive Element (TRE) 1 and an increase in PVL levels [17]. Furthermore, it has been
observed that non-synonymous mutations of the HTLV-1 tax gene could display markedly attenuated
abilities to transactivate the provirus [18].
Over the last decade, a sensitive and specific nested polymerase chain reaction (n-PCR)
assay able to confirm HTLV-1/2 infections in individuals with an indeterminate profile or HTLV
positive but not typeable results by WB became an important tool for diagnosis [19,20]. Years later,
quantitation of HTLV-1 proviral load (PVL) by quantitative real-time PCR (qPCR) was implemented
for the follow-up of patients with associated pathologies worldwide [21–23]. Recently, both qPCR
and multiplex (mqPCR) have been proposed as molecular testing for the confirmation of HTLV-1/2
diagnosis, aimed to address the issue of indeterminate results. However, according to reported data,
these techniques still show sensibility problems [24,25].
As a consequence of frequent indeterminate WB results leading to difficulties in interpretation
and counseling in our country, this study aims to (i) define the prevalence and banding profile
frequency of cases with indeterminate results by WB among different populations from Argentina;
(ii) evaluate whether a low PVL in HTLV-1 positive individuals is one of the causes of these results;
and (iii) identify the presence of punctual mutations, both in Long Terminal Repeats (LTR) and tax
regions, of indeterminate cases.
2. Results
2.1. Prevalence Studies
Prevalence of WB indeterminate results corresponding to samples from four different
populations of Argentina is shown in Table 1. Three of them, Men who have Sex with Men
(MSM), Injecting Drug Users (IDUs), and Female Sex Workers (FSW), belong to a previous
epidemiological study [26]. The remaining one, the HTLV Diagnosis and Confirmation population
(HDC), is composed of individuals referred from blood banks or hospitals to our Institute. The global
methodology, including the number of samples tested at each step, is illustrated in Figure S1. The
total number of WB indeterminate samples (IS) and, of those, the ones that were later confirmed as
HTLV-1 or HTLV-2 positive by molecular techniques, are also shown in Table 1.
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Table 1. Prevalence of HTLV-1/2 infection and frequency of WB indeterminate patterns in
four populations of Argentina. MSM: Men who have Sex with Men; IDU: Injecting Drug Users;
FSW: Female Sex Workers; HDC: samples received at a Reference Institute for HTLV Diagnosis
and Confirmation (HDC) from blood banks or hospitals of Argentina. ELISA: enzyme-linked
immunosorbent assay. PA: particle agglutination.
Reactive
by PA
or ELISA
Indeterminate
samples
(IS) n (%)
IS
Confirmed
HTLV-1+
by n-PCR
n (%)
IS
Confirmed
HTLV-2+
by n-PCR
n (%)
Total HTLV-1
Prevalence
% (n/N)
Total HTLV-2
Prevalence
% (n/N)
MSM (N=667) 26 11 (1.65) 3 (27.28) 0 (0) 0.45% (3/667) c 0% (0/667)c
IDU (N=173) 36 4 (2.31 ) 4 (100 ) 2 b (100 ) 4.62% (8/173) c 15.6% (27/173) c
FSW (N=613) 25 3 (2.12) 3 (23.10 ) 0 (0 ) 1.46% (9/613) c 0.2% (1/613) c
HDC (N=578) 207 30 (5.19 ) 3 (15.79) a 2 (10.53)a 18.8% (109/578) 5.36% (31/578)
Total 294 48 (16.33) 13 (35.13) 4 (10.81) 6.35%(129/2031) 2.90% (59/2031)
aOut of 30 seroindeterminate samples, only 19 could be tested by molecular techniques, as no DNA was
available for the other 11. bThese two samples were HTLV-1/2 co-infected. cData reported by Berini et al.
2007 [26].
The different WB indeterminate banding patterns are detailed in Table 2 for all samples from
the HDC population (n=30), including positive and negative ones by n-PCR. The banding patterns
corresponding to the other three populations were previously described by Berini et al. 2007 [26].
Table 2. Description of WB indeterminate patterns for positive and negative samples by n-PCR among
578 samples received at a Reference Institute for HTLV Diagnosis and Confirmation (HDC) from blood
banks or hospitals of Argentina.
WB Indeterminate
Banding Pattern N
HTLV-1/2
Negative
HTLV-1/2
Positive Not Performed
GD21 6 3 1 2
GD21 + others 7 3 3 1
rgp46-1 and/or 2 4 1 1 2
p19 2 2 0 0
p19 + p24 4 2 0 2
p19 + others 1 0 0 1
HGIP 6 3 0 3
Total 30 14 5 11
The following experiments were performed in nine out of 13 seroindeterminate confirmed
HTLV-1 positive cases found among the four studied populations, as samples from the other four
were scarce. Figure 1 shows the banding pattern in each case.
2.2. Performance of the qPCR
The qPCR quantitation limit was 34 albumin copies/reaction and three pol copies/reaction.
Samples with seroindeterminate results were run together, and an additional dilution was added
to pol standard curve, as lower Threshold Cycle (Ct) values were expected. Acceptance criteria
were accomplished and linearity was maintained (R2> 0.99). The intra-assay coefficient of variation
(CV) was directly proportional to viral load levels: 14% at high load (>10 HTLV-1 copies/100 cells),
9% at medium load (1–10 HTLV-1 copies/100 cells), and 7% at low load (<1 HTLV-1 copy/100 cells);
inter-assay CV at high loads was 24%. Of the 52 samples, PVL was detected in 51 and successfully
quantified in 44 of them, including 25 pathology cases that were not in treatment at the time
of the sample extraction (G1), 15 samples from asymptomatic carriers (AC) (G2), and four from
seroindeterminate cases (G3), also AC. PVL was detected but not quantified in three G2 and four G3
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samples, as the acceptance criteria was not met because of variable Ct values for pol gene. This viral
gene was not detected in one of the G3 samples, although it could be amplified by n-PCR.
Figure 1. Western blot patterns of indeterminate cases confirmed HTLV-1 positive by n-PCR.
Seroreactivity pattern using the MPD HTLV Blot 2.4 kit, which contains a recombinant GD21 (common
for HTLV-1 and HTLV-2) and two synthetic peptides (rpg46-I and rpg46-II), specific either for HTLV-1
or HTLV-2. “HTLV-1”: HTLV-1 positive control. “C-“: negative control. 44–52: banding profile for
each of the nine seroindeterminate cases analyzed.
2.3. PVL Values
Individual PVL values are shown in Table 3. Median PVL values and standard errors were
4.78 (2.4), 2.38 (1.02), and 0.15 (0.07) HTLV-1 copies/100 PBMCs for G1, G2, and G3, respectively;
a significant difference could be observed between the three groups (p = 0.003), as shown in Figure 2a.
The difference was also significant (p = 0.005) when samples with seropositive WB results were
analyzed as a single group [G1 + G2]. As shown in Figure 2b, no significant difference (p = 0.07)
was observed when samples from acute leukemia (ATL; n = 4) were compared with HAM/TSP
ones (n = 21).
2.4. PVL Distribution
Regarding WB indeterminate samples, all successfully detected PVLs (8/9) were lower than
1 HTLV-1 copy/100 cells. Concerning G1 and G2 samples, an overlap in the range of PVL values
was observed (Table 4). In three cases, viral loads below 1 HTLV-1 copy/100 cells were observed in
individuals with pathology (12%).
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Table 3. Age, gender, and individual proviral load values (PVL) of cases confirmed as HTLV-1
positive by nested PCR (n-PCR). Samples were classified as Group 1: positive samples by WB from
individuals with pathology that are not on treatment (n = 25), Group 2: positive samples by WB from
asymptomatic carriers (AC) (n = 18), and Group 3: indeterminate samples by WB from AC (n = 9).
Codes for 14 LTR and/or tax sequences are detailed in brackets. Indeterminate patterns for G3 are
also described in brackets. PVLs are expressed as HTLV-1 copies/100 PBMCs.
Sample N
(Sequence Code) Group Age Gender PVL
1 1- Leukemia 53 M 33.9768
2 1- Leukemia 66 F 40.1995
3 (ATL1) 1- Lymphoma 48 F 1.2974
4 (ATL2) 1- Leukemia 67 F 12.4920
5 1- HAM/TSP 43 F 0.7081
6 1- HAM/TSP 14 F 8.9051
7 1- HAM/TSP 27 F 3.1244
8 1- HAM/TSP 38 F 1.6633
9 1- HAM/TSP 52 F 8.5679
10 1- HAM/TSP 65 M 5.3882
11 1- HAM/TSP 37 F 1.2808
12 1- HAM/TSP 51 F 4.7829
13 (Neu28) 1- HAM/TSP 42 F 13.0850
14 (Neu14) 1- HAM/TSP 39 F 1.0119
15 1- HAM/TSP 52 M 35.0971
16 1- HAM/TSP 59 F 12.8610
17 1- HAM/TSP 50 M 1.3508
18 1- HAM/TSP 56 F 29.5394
19 1- HAM/TSP NA M 0.1183
20 1- HAM/TSP 26 F 3.1234
21 1- HAM/TSP 71 F 10.4542
22 1- HAM/TSP 35 M 0.5227
23 1- HAM/TSP 67 F 1.6661
24 1- HAM/TSP 52 M 15.5252
25 1- HAM/TSP 49 M 4.0326
26 2 50 M 12.4340
27 2 64 M 1.8929
28 2 50 M 0.0832
29 2 46 F 1.2681
30 (ASYAR3) 2 35 M 4.6143
31 (ASYAR2) 2 26 F 0.7502
32 2 47 F 0.2476
33 2 25 M 8.4668
34 2 33 M 2.3861
35 2 39 F 2.8778
36 (ASYAR1) 2 47 F 0.4813
37 2 52 F <3 copies/ reaction
38 2 NA F <3 copies/ reaction
39 2 38 F 0.1832
40 (BDAR20) 2 38 M 3.9461
41 2 57 M 5.9663
42 2 NA M <3 copies/ reaction
43 2 46 M 10.5358
44 3 (p19) 59 M 0.0013
45 3 (p19) 24 M 0.3365
46 (BDAR21) 3 (GD21) 28 M 0.1493
47 (BDAR18) 3 (p24, GD21) 52 M 0.1452
48 (FSW8) 3 (HGIP) 32 F <3 copies/ reaction
49 (FSW9) 3 (p19) 52 F <3 copies/ reaction
50 (FSW7) 3 (p19) 25 F <3 copies/ reaction
51 (BDAR19) 3 (GD21) 31 M <3 copies/ reaction
52 3 (HGIP) 21 M pol not detected
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Figure 2. Individual proviral load values (PVLs). PVLs are expressed as HTLV-1 copies/100 PBMCs.
(a) Samples are classified as Group 1: positive samples by Western blot (WB) from individuals with
pathology that are not on treatment (n = 25), Group 2: positive samples by WB from asymptomatic
carriers (AC) (n = 15), and Group 3: indeterminate samples by WB from AC (n = 4); PVL values are
shown. A significant difference is observed between the three groups (p= 0.003) (GraphPad Prism
V5). (b) PVLs for samples of Group 1, classified by disease: ATLL (n = 4) or HAM/TSP (n = 21) are
shown, p= 0.07.
Table 4. Individual proviral load values (PVL) distribution by groups (G). G1: positive samples by
Western blot (WB) from individuals with pathology; G2: positive samples by WB from asymptomatic
carriers (AC); and G3: indeterminate samples by WB from AC. PVLs are expressed as HTLV-1
copies/100 PBMCs.
PVL Range G1 (n=25) G2 (n=18) G3 (n=8)
<1 12% 44.4% 100%
1–10 52% 44.4% -
>10 36% 11.2% -
2.5. PVL Association with Gender, Age, and Optical Density
A moderate correlation (S=0.56) between PVL values and age at the moment of the sample
extraction was observed in G1, which included patients with pathology who were not in treatment.
Meanwhile, there was a significant association between PVL and gender in G2 (p = 0.01) (Figure 3).
No correlation was observed in G3. Significantly lower optical density values were observed in most
of the seroindeterminatesamples (n = 6/7), when compared with plasma samples from G1 and G2
selected randomly.
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Figure 3. Median individual proviral loads (PVL) of G2 samples distrubuted by gender. A significant
association (p=0.01) is observed between PVL and gender in Western blot (WB) positive samples from
asymptomatic carriers (AC) distributed as: Males (n = 9) and Females (n = 6). Median PVL values
were 4.61 in males and 0.61 in females. Median values together with interquartile ranges are shown.
2.6. HTLV-1 Phylogeny
A rooted neighbor-joining (NJ) tree of 134 HTLV-1 strains based upon a 458-bp fragment of
the LTR region was performed, including 14 new strains from Argentina (G1: n=4; G2: n = 4;
G3: n = 6); three G3 sequences could not be obtained. Cosmopolitan subtype HTLV-1a was clearly
separated from HTLV-1 subtypes b, c, d, e, f, and g, with a bootstrap value of 69%. Within the
cosmopolitan subtype, five subgroups were identified as previously described [4]. Although all of
them were consistently separated by NJ, only two subgroups, West African/Caribbean subgroup
C and North African subgroup D were well supported, showing higher bootstrap values than
75% (90% and 96%, respectively). Thirteen strains clustered within the cosmopolitan subtype
transcontinental subgroup A, while the remaining one (N 13, Neu28) from G1 clustered among
sequences from Brazil and Peru previously reported by our group as Divergent Strains (Figure S2).
Of these, five strains (ASYAR2, N31; BDAR20, N40; ASYAR3, N30; ATL2, N4; and Neu14, N14)
grouped with sequences from the Big Latin American cluster and three sequences (BDAR21, N46;
ATL1, N3; and BDAR19, N51) from the Small Latin American cluster. All eight sequences from the
Latin American clusters grouped with Amerindian strains and other populations from Argentina
previously reported by our group. One of the G3 strains (FSW7, N50) grouped in the South African
cluster along with one Argentine blood donor (BD1) and one Peruvian female sex worker (FSW1)
residing in Argentina. The remaining four (BDAR18, N47; FSW8, N48; FSW9, N49; and ASYAR1,
N36) clustered within the transcontinental group, near the other Argentine sequences previously
reported by our group but not in any specific cluster.
2.7. Sequence Analysis
LTR and tax genes could be amplified in eight and four of all the seroindeterminate cases
analyzed, respectively. Of those, six LTR and two tax sequences could be obtained with high quality,
despite having repeated the procedure several times and assayed different DNA amounts with the
remaining samples. A total of 25 mutations were detected among LTR sequences from G3 samples,
of which seven were linked to geographical subtypes. Four mutations were observed in more than
one sequence and the remaining 14 in only one, as detailed in Table 5. Of them, one mutation in the
TRE-1 domain was present in the distal (dr) and one in the central (cr) region of the LTR. Regarding
the TRE-2, two punctual mutations (8522T>C, 8545G>A) were observed in sample N 50, while the
other three were present in most Argentine sequences. While not found in any of the LTR sequences
from G3, a mutation was observed in the distal region of TRE-1 (8403A>G) in 50% of the remaining
sequences, which corresponded to samples with positive HTLV-1 results by WB and a significant
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difference (p = 0.03) between these frequencies was established. As for sequences from patients with
pathology, eight (2 ATL and 6 HAM/TSP) out of 15 had this same mutation, thus maintaining the
significance (p = 0.04).
Tax sequences showed 12 punctual mutations at the nucleotide level; of them, five were present
in most of the Argentine sequences. Through the analysis of non-synonymous (NS) mutations in
functional domains of the Tax protein, four amino acidic mutations were detected, two of them
corresponding to geographical subtypes (A221V, S304N). The remaining mutations (H43P and
M154V) were detected in sequences N 46 and 47, respectively; H43P is located within the Nuclear
Localization Signal domain, the Zn Finger, and CREB activation by Tax, while M154V is in the NF-κB
activation region and the Dimerization Domain.
Table 5. Punctual mutations detected in LTR (U-3, R, and U-5) and tax gene sequences of
indeterminate Western Blot samples confirmed as HTLV-1 positive by nested PCR. Six LTR and two
tax sequences from seroindeterminate samples were analyzed, together with four sequences from
HTLV-1 patients with pathology, four from HTLV-1 asymptomatic carriers, and 44 sequences from
Argentina, previously obtained by our group and available in Gene Bank. Geographical: mutation
linked to geographical subtypes; dr: distal region; cr: central region.
Punctual Mutation Sequence N Region Punctual Mutation Sequence N Region
8295G>A 46- 48 LTR; U-3 8718C>T 51 LTR; R
8367C>A Geographical LTR; U-3 8779T>C 47 LTR; R
8381G>A 48 LTR; U-3 8822G>A 46 LTR; R
8391G>A 46 LTR; U-3 8828A>G 47 LTR; R
8392G>A 46 LTR; U-3 8912T>C 46- 47 LTR; U-5
8420C>T 49 LTR; U-3; TRE-1; dr 8955G>A 47 LTR; U-5
8428_8429insA Geographical LTR; U-3; TRE-1 7383C>T 46 tax
8446G>A Geographical LTR; U-3; TRE-1 7398C>T 46- 47 tax
8471G>T 50 LTR; U-3; TRE-1; cr 7401C>T Geographical tax
8509A>G Geographical LTR; U-3; TRE-2 7431G>A 47 tax
8509_8511delA Geographical LTR; U-3; TRE-2 7448A>C 46 tax
8522T>C 50 LTR; U-3; TRE-2 7780A>G 47 tax
8545G>A 50 LTR; U-3; TRE-2 7914T>C Geographical tax
8546T>C Geographical LTR; U-3; TRE-2 7920C>T Geographical tax
8606C>G Geographical LTR; U-3 7933C>T 47 tax
8606C>A 49- 51 LTR; U-3 7982C>T Geographical tax
8632G>A 46 LTR; U-3 8001A>G 46 tax
8655G>T 46 LTR; U-3 8231G>A Geographical tax
8665C>T 46- 48 LTR; R
3. Materials and Methods
3.1. Samples
A retrospective cross-sectional study was carried out on four different populations. Of those,
Injecting Drug Users (IDU; n = 173), Female Sex Workers (FSW; n = 613), and Men who Have Sex with
Men (MSM; n = 667) have been previously recruited and studied by our group; the corresponding
HTLV-1/2 prevalence was reported in Berini et al. [26]. The fourth population included individuals
with previous serological reactive results for HTLV-1/2 and/or with symptoms of HTLV-1 associated
pathologies, whose samples have been sent from blood banks and/or hospitals from all over
Argentina to our Institute for HTLV diagnosis or confirmation (HDC) between January 2011 and
January 2014. The prevalence of the former population is reported here. All participants provided
a written informed consent and the project was approved by the Institutional Review Board of
Nexo Civil Association, Argentina. Samples confirmed as HTLV-1 positive by molecular techniques
were classified in three different groups (G). G1 consisted of all the positive samples by WB from
individuals with pathology who were not on treatment received for HDC between 2011 and 2014:
21 HAM/TSP patients and 4 Acute Leukemia Lymphoma (ATLL) patients. G2 included 18 WB
positive samples from asymptomatic carriers (AC), who were chosen randomly for this study.
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G3 included 9 indeterminate samples by WB, also from AC. Serological and socio-demographic
information of all nine G3 individuals is described in Supplementary Table 1.
3.2. Diagnostic Algorithm
Antibody screening for HTLV-1/2 was performed by particle agglutination technique
(SERODIA-HTLV-I, Fujirebio, Tokyo, Japan) and/or by enzyme-linked immunosorbent assay
(ELISA) (Murex HTLV-I+II, Abbott Laboratories Argentina, Buenos Aires, Argentina or HTLV
I&II Ab v. ULTRA, Dia.Pro, Milan, Italy). Reactive samples were subjected to WB confirmation
(HTLV blot 2.4, Genelabs Diagnostics, Science Park, Singapore). A WB was scored as HTLV-1 or
HTLV-2 positive, untypeable, indeterminate, or negative according to the manufacturer’s criteria.
For molecular confirmation of indeterminate or HTLV-positive samples by WB, DNA was
extracted from peripheral blood mononuclear cells (PBMCs) by column extraction (ADN PuriPrep-S
kit, Highwayr, Inbio, Tandil, Argentina) and analyzed with “in-house” n-PCR for HTLV-1 and
2 pol and tax regions as previously described [19,20]. PCR was considered positive when amplicons
from at least one amplification reaction were clearly detectable following agarose gel analysis [11].
Samples with non-reactive results by PA or ELISA were also further confirmed by n-PCR in
order to avoid misdiagnosis in patients on retroviral treatment (because of other infections) and
immune-compromised patients.
3.3. DNA Quantitation
Absolute quantitation of PVL was performed by real-time SYBR Green PCR, using an
ABI Prism 7500Prism System (Applied Biosystems, Foster City, CA, USA).The HTLV-1 pol gene
was amplified using 5 µL DNA, 12.5 µL SYBR Green PCR Master Mix (Applied Biosystems),
and 200 nM of each primer (SK110-1: 5’-CCCTACAATCCAACCAGCTCAG-3’ and SK111-1:
5’-GTGGTGAAGCTGCCATCGGGTTTT-3’). PCR amplification of the albumin gene (ALB-S:
5’-GCTGTCATCTCTTGTGGGCTGT-3’ and ALB-AS: 5’-AAACTCATGGG AGCTGCTGGTT-3’) was
performed as a separate reaction, as an endogenous reference to avoid variation due to differences in
either the PBMC number or the DNA extraction method used. Cycle conditions were the following:
2 min at 50 C and 10 min at 95 C followed by 40 cycles of 15 s at 95 C and 1 min at 65 C. Melting
curves were performed after the end of the amplification cycles to validate the specificity of the
amplified products. Standard curves were generated using 10-fold serial dilutions of DNA from MT2
cells (104–100), and normalized to two copies of the HTLV-1 pol gene and two copies of the cellular
albumin gene per MT2 cell [27]. All standard dilutions, controls, and individual samples were run
in triplicate for both HTLV-1 and albumin DNA quantitation. Standard curves were accepted when
slopes were between –3.10 and –3.74 and the R2 was >0.99 [28]. The accuracy of the diagnostic
test was assessed by measuring intra-assay and inter-assay variability. Intra-assay variability was
evaluated by calculating the coefficient of variation (CV) of three viral load replicates from three
DNA samples in three different ranges defined as low (<1 HTLV-1 copy/100 cells), medium
(1–10 HTLV-1 copies/100 cells), and high (>10 HTLV-1 copies/100 cells). Inter-assay variability
was calculated by measuring the CV for a high PVL sample in three independent runs. CV rather
than standard deviations were used as they are not affected by the PVL absolute value. HTLV-1
proviral load was reported as [(pol average copy number)/(albumin average copy number/2)]*100
and expressed as the number of HTLV-1 copies/100 cells.
3.4. Molecular Analysis
Indeterminate samples were subjected to hemi-nPCR, aimed at amplifying LTR
and tax genes. Amplification of the 3’ LTR region was performed using 8200LA
(5’-CTCACACGGCCTCATACAGTACTC-3’) and R2 (5’-GTGCTATAGGATGGGCTGTCGC-3’)
as outer primers and 3VINT (5’-GAACGCRACTCAACCGGCRYGGATGG-3’) and 3LTRf
(5’-TCCCCATTTCTCTATTTTTAACG-3’) as inner primers (528 bp, ATK-1 genome position
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8196–8699). Amplification of the tax region was carried out with outer primers HFL75
(5’-GCTATAGTCTCCTCCCCCTGC-3’) and 3VINT (5’-GAACGCRACTCAACCGGCRYGGATGG-3’)
and inner primers TaxF (5’-ATGGCCCACTTCCCAGGGTT-3’) and TaxR (5’-TCAGACTTCTGTTTCTCGGA-3’),
specific for HTLV-1. A slight modification was made to the protocols described elsewhere, in order to
amplify tax and LTR genes in seroindeterminate samples by enhancing the DNA amount [29]. Direct
sequencing reactions were done using a Big Dye Terminator 3.1 Cycle Sequencing RR-100 (Applied
Biosystems). Sequences were generated on a 3500xL Genetic Analyzer AB/HITACHI according
to the manufacturer’s instructions. Sequences were edited manually (Sequencher 4.8) and then
aligned using Clustal W (BioEdit 7.0.4.1 sequence alignment editor). For the sequence analysis of
both genes, the ATK-1 genome was included as a reference prototype sequence and four samples
from G1 together with four samples from G2 included as controls. Furthermore, 50 LTR sequences
were also added, all of them corresponding to samples from Argentina and available in PubMed.
MEGA software v. 5.2.2 was used for translation of tax gene sequences, based on the conventional
genetic code.
To construct a comprehensive phylogenetic dataset, 14 of the LTR sequences (six seroindeterminate samples,
four from HTLV-1 patients with pathology, and four from HTLV-1 AC) (See 5.5 “Accession numbers”)
were aligned along with 120 HTLV-1 reference strains obtained from the GenBank database,
preferentially chosen because they were either from Argentina or from neighboring countries with
high migration rates to Argentina. The Mel 5 reference strain (Melanesian origin, subtype c) was used
as an outgroup. Once aligned, the dataset consisted of 458 bp corresponding to the 3´ LTR region. The
phylogenetic analysis was performed by neighbor joining (NJ) using MEGA 5.2 and the tree topology
was visualized with TreeView (http://taxonomy.zoology.gla.ac.uk/rod/treeview.html) [30].
3.5. Accession Numbers
Accession numbers corresponding to all new sequences mentioned here are detailed below.
ASYAR2LTR: KT633516; BDAR20LTR: KT633517; FSW7LTR: KT633518; ASYAR3LTR: KT633519;
BDAR19LTR: KT633520; FSW8LTR: KT633521; Neu14LTR: KT633522; BDAR18LTR: KT633523;
BDAR21LTR: KT633524; FSW9LTR: KT633525; ASYAR1LTR: KT633526; ATL1tax: KT633527;
Neu2tax: KT633528; ASYAR2tax: KT633529; BDAR18tax: KT633530; ATL2tax: KT633531;
ASYAR1tax: KT633532; ASYAR3tax: KT633533; BDAR20tax: KT633534; Neu14tax: KT633535;
BDAR21tax: KT633536. The following numbers correspond to the sequences obtained from
GenBank for the molecular analysis. MEL5 (L02534); Efe1 (Y17014), ITIS (Z32527), PH236 (L76307);
2810YI (AY818432); Lib2 (Y17017); pyg19 (L76310); HS35 (DI3784), FrGu1 (AY324785), BO (U12804),
Pr52 (U12806), Pr144 (U12807), Bl1.Peru (Y16481), RKl4.Peru (AF054627), BCl2.1 (U32557),
H5 (M37299), Ni1-3.Peru (Y16484, Y16487, Y16485), ATL-YS (U19949), ATK-1 (J02029),
MT4.LB ( Z31661), Br4 (AY324788), Bl3.Peru (Y16483), Neu13 (EU622623), Neu10 (EU622620),
MT2 (L03562), 73RM (M81248), Ar11 (AY324777), FSW6 (EU622605), MSM2 (EU622609),
BD7 (EU622588), Sur229-30 (AY374468, AY374466), BD3 (EU622586), BD10 (EU622590), TBH1-3
(L76026, L76025, L76034), FSW1 (EU622600), BD1 (EU622584), BD8 (EU622589), Gya468 (AY374459),
Gya813 (AY374462), SurHM22 (AY374467), Gya542 (AY374460), BOI (L36905), BD13 (EU622593),
BRRJ136.96 (DQ323759), KUW1-2 (L42253, L42255), IRN2 (U87261), CH26 (D23690), Abl.A
(U87264), BCl1.2 (U32552), BRRP445 (DQ323755), BRRJ276.95 (DQ323750), BRRJ56.00 (DQ323754),
BRRJ53.97 (DQ323753), Neu4 (EU622615), PW2 (EU622625), Neu5 (EU622616), MSM4 (EU622611),
IDU4 (EU622608), Neu3 (EU622614), BD2 (EU622585), CAM (AF063819), BRRJMDP (DQ323751),
ARGSOT (AF007755), AMA (X88871), CMC (X88872), TBH4 (L76028), BRRP495(DQ323755), FSW4
(EU622603), Me3.Peru (Y16480), Ar55 (AY324782), FSW5 (EU622604), Sur1597 (AY374465), Gya572
(AY374461), Neu1 (EU622612), FSW2 (EU622601), JCP (X88875), BRRJFA (DQ323757), Me1.Peru
(Y16478), MASU (X88877), FCR (X88873), BRRJ86.97 (DQ323760), MAQS (X88876), Ar5 (AY324783),
Qu2.Peru (Y16476), Me2.Peru (Y16479), Qu3.Peru (Y16477), J37 (FJ751855), BD16 (EU622596), IDU1-3
(EU622598, EU622606, EU622607), BD15 (EU622595), BD14 (EU622594), BD12 (EU622592), Neu11
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(EU622621), BD11 (EU622591), J77 (FJ758161), J43 (FJ751856), BD4 (EU622587), J68 (FJ751858),
J20 (FJ751854), Neu12 (EU622622), Ar49 (AY324793), Ar15 (AY324778), PW1 (EU622624), FSW3
(EU622602), Qu1.Peru (Y16475), Neu7 (EU622618), ARGDOU (AF007751), Neu8 (EU622619), BD17
(EU622597), J47 (FJ751857), MSM3 (EU622610), Neu2 (EU622613).
3.6. Statistical Analysis
Data analysis was performed using the Kruskal–Wallis non-parametric method; when two
groups were compared, the Mann–Whitney–Wilcoxon test was used. To evaluate the presence of
association between PVL and age of individuals, correlation was determined based on Spearman
coefficient (S). GraphPad Prism (version 6.03) software was applied and significant differences were
defined as p < 0.05.
4. Discussion
HTLV indeterminate WB patterns have been reported worldwide, although they are more
frequent in tropical areas [31,32]. Most of these reports refer to blood donors, and seroindeterminate
frequency varies according to HTLV-1/2 endemicity (i.e., the geographical area studied) [27,33].
In this study, we report for the first time in our country the prevalence of indeterminate WB
results among at-risk populations: 2.31%, 2.12%, and 1.65% for IDUs, FSW, and MSM, respectively.
Moreover, the prevalence of indeterminate WB patterns (5.19%) in the HDC population recruited in
our Institute was higher than the one reported in our country for blood donors (0.1%), as expected due
to a biased population [27]. On the other hand, it must be considered that screening in our laboratory
has always been performed with the most efficient assays available in the country. Concerning the
indeterminate WB banding patterns in the HDC population (both positive and negative cases by
n-PCR), GD21 (alone or with other bands) and HGIP were the most frequent. Several studies have
demonstrated the presence of HGIP patterns mostly among blood donors, and it has been suggested
that generally these are not caused by HTLV-1 infection [32]. Nonetheless, as reported previously by
our group, two HGIP cases corresponded to samples that turned out positive for HTLV-1 infection
(one blood donor and one IDU) [10]. Regarding the “N pattern” recently described by Filippone et al.,
it was not observed neither in the HDC population, nor in at-risk populations (pattern described in
Berini et al [26]) [11].
There are few reports suggesting that low HTLV-1/2 PVL could cause indeterminate WB
patterns in samples from infected individuals [16,34]. Regarding HTLV-1, low PVL levels for these
cases were suggested, especially in the ones in which no PVL could be successfully quantified,
although no direct comparisons with seropositive patients were performed [35–37]. In this study, PVL
values were compared between two groups with positive WB results: G1 (individuals with pathology
without retroviral treatment) and G2 (asymptomatic carriers: AC). A significant difference was
observed between them, in line with previously published data [21,22]. Furthermore, a third group
was included consisting of nine samples from AC with seroindeterminate WB, of which four PVLs
could be determined. Even when considering the small sample size of G3, a significant difference
was observed between these three groups. Although a seroconversion could not be discarded in
the indeterminate cases, these data demonstrate that in some cases indeterminate WB results could
be associated with low HTLV-1 PVL; a low viral replication rate may consequently trigger a weak
immune response and low concentrations of anti-HTLV-1 antibodies.
Regarding age and gender, it was determined that these variables were associated with PVL
levels among G1 and G2, respectively. While Vakili et al. observed no significant association between
PVL in HAM/TSP patients and healthy carriers with age and gender, it has been reported that
for both HTLV-1 and 2 infections, women have lower PVL levels than men, consistent with our
results [38–40]. In contrast, Hisada et al. showed no gender differences in PVL [41]. Thus, further
studies should be performed in order to clarify this issue. Regarding serological status, Manns et al.
reported in 1999 that the anti-HTLV-1 antibody titer had a positive correlation with PVL levels, and
5653
Viruses 2015, 7, 5643–5658
years later, Akimoto et al. confirmed these results [42,43]. In this study, and similarly to what has
been reported by Filippone et al., the optical density values obtained were lower for most of the
seroindeterminate profile plasma samples when compared to HTLV-1 WB-positive ones [11].
As for phylogeny, all 14 new strains described in this study belonged to the cosmopolitan
subtype and most of them classified within the transcontinental subgroup A (one sample classified
as divergent). Half of the G3 sequences did not group in any specific cluster, while two grouped in
the small Latin American cluster (BDAR19, BDAR21) and one in the South African cluster (FSW7),
together with other sequences previously reported by our group (FSW1 and BD1) [44]. These data
confirm our previous publication concerning the presence of HTLV-1 transcontinental and African
strains circulating in Argentina, although most of the infected individuals in our study were not
of black origin, supporting the hypothesis of multiple introductions of HTLV-1 of the cosmopolitan
subtype in the New World [5].
Even though some of the observed mutations in LTR and tax genes were linked to geographical
subtypes, others were further analyzed in order to establish their relevance, as it is well known
that during replication and transcription the LTR/Tax system is extremely important. The promoter
region LTR responds to the transactivation mediated by the Tax protein, which directly interacts by
binding the DNA or indirectly by binding cellular transcription factors, in the Tax regulation elements
known as TRE-1 and TRE-2 [45]. Although mutations in sequences from G3 were observed both in
the distal and central regions of TRE-1, no significant associations were established given the number
of mutated sequences. The same is valid for the TRE-2 region, which can also mediate transactivation
by Tax-1 [46,47], considering that it contains binding sites for a large number of transcription factors,
including AP-2, HNF-3, Ets family members, NFκB, and Sp1 [48]. Interestingly, we have not observed
the 8403A>G mutation (distal region of TRE-1) in any of the G3 sequences, although it was present
in 50% of the remaining sequences, all of them positive by WB. Therefore, a significant association
was established between the presence of this mutation and seropositivity. Particularly, 53% of
sequences from patients with pathology were mutated in base 8403, consistent with a report from
Brazil, in which this mutation was significantly associated with high PVL values [17]. Regarding
the Tax protein, non-synonymous mutations in the CREB activation domain as well as in the
NF-κB and Zn Finger activation domains were detected. Previous data indicate that mutations in
these regions displayed markedly attenuated abilities to transactivate the provirus and to reduce the
ability to induce nuclear expression of NF-κB [18]. Whether the presence of mutations observed in
this study could explain a diminished transactivation activity of Tax protein and therefore a low
PVL still remains to be determined. Only functional studies would indicate their possible impact on
indeterminate WB profiles.
Considering diagnosis, indeterminate WB results cannot be avoided without an improvement
of serological commercial kits aimed at enhancing sensibility and specificity. Thus, and taking into
account the high prevalence of these seroindeterminate cases worldwide [10,11,49], the usefulness of
serological confirmation is questionable, highlighting the difficulties in interpretation and counseling.
Seroindeterminate results represent a big challenge for health professionals, especially in those
countries with endemic areas and no national programs for controlling HTLV infection. Furthermore,
WB kits are far more expensive than n-PCR, being a relevant factor for the healthcare system. Costa
and Thorstensson et al. have recommended different strategies for reducing costs and improving
the accuracy of the diagnosis [24,50]. While both proposed two EIAs for screening, Costa recommends
qPCR to confirm the infection. Even though qPCR is actually the standard method for PVL
quantitation, other technologies have also been introduced. Recently, an mq-PCR testing algorithm
for the diagnosis of HTLV-1/2 infection has been proposed [25]. Nevertheless, in some serologically
confirmed positive cases, PVL could not be detected, especially in HTLV-2 samples [25,51]. In that
context, Brunetto et al. reported the utility of digital droplet PCR (ddPCR) in the quantitation of
HTLV-1 PVL [52]. They postulate that, even though both methods show a strong correlation and
similar performance, ddPCR exhibits lower inter and intra-assay variability as it is based on a
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Poisson algorithm for quantitation of genes instead of the standard curve used in qPCR [52]. On the
other hand, another study showed a higher sensitivity for qPCR compared to ddPCR when detecting
cytomegalovirus in clinical samples [53]. Based on these data, more studies should be performed
in order to establish the most efficient methodology for HTLV-1/2 PVL quantitation. Furthermore,
a consensus regarding qPCR data interpretation and analysis for HTLV-1/2 PVL quantitation, as well
as a universal expression unit, should be achieved in order to avoid confusion and misunderstanding.
Besides, most HTLV-1/2 endemic areas correspond to developing countries and access to qPCR
equipment is not always possible.
Therefore, we propose to re-evaluate the diagnostic algorithm, considering molecular
confirmation by n-PCR for reactive samples, instead of qPCR, right after the combination of two
screening tests. This alternative would avoid serological confirmation by WB, the most expensive
stage of the diagnosis algorithm, until a better confirmation technique is available and standardized.
Further studies with significant panels including HTLV-1, HTLV-2, and indeterminate samples should
be carried out in order to establish whether it is time saving, effective, and less expensive.
5. Conclusions
This study describes the prevalence of indeterminate WB patterns among different populations
from Argentina and demonstrates that in some cases these profiles may be associated with low
HTLV-1 PVL. Mutations in LTR and tax have been described among both indeterminate and positive
HTLV-1 cases, highlighting 8403A>G in the distal region of TRE-1, already related to high PVL. Still,
the functional relevance of these mutations remains to be determined.
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